Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson
FDA & EMA approvals for rare genetic diseases are fast and require clinical studies with small number of patients Ramat...
Brain
New Novartis Phase III data demonstrate meaningful efficacy and safety results of intrathecal onasemnogene abeparvovec in broad patient population with SMA
New Novartis Phase III data demonstrate meaningful efficacy and safety results of intrathecal onasemnogene abeparvovec in broad patient population with...
Lipozem Reviews (Is It Safe And Legit To Use?) Ingredients, Side Effect Complaints, And Weight Loss Benefits!
LAKELAND, Fla., March 19, 2025 (GLOBE NEWSWIRE) -- Lipozem is a weight loss supplement crafted to support burning fat without...
DarwinHealth Recognized and Honored as One of the Top 10 Most Innovative Biotech Companies: Named to Fast Company’s Prestigious Annual List of the World’s Most Innovative Companies of 2025
NEW YORK, March 18, 2025 /PRNewswire/ -- DarwinHealth is proud to have been named to Fast Company's prestigious list of the...
brain.space ANNOUNCES $11M SERIES A FUNDING ROUND TO ACCELERATE DESIGN OF BRAIN DATA-DRIVEN MENTAL MODELING
Neurotechnology Pioneer Utilizes Standardized Brain Data to Predict Human Behavior, Enhance Digital Systems across Consumer, Health, Defense, and Aerospace TEL...
Mindbody Partners with Rokt to Deliver Highly Relevant Online Ad Experiences to Its Fitness and Wellness Members
NEW YORK, March 18, 2025 /PRNewswire/ -- Mindbody, the leading experience technology platform for the wellness industry, today announced it...
Madison Scientific Closes $7M in Seed Financing
Funds will be used to advance development of the company's SmartShunt™ System that aims to address current challenges with existing hydrocephalus...
NeuroOne® CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today’s Marketplace
EDEN PRAIRIE, Minn., March 18, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a...
March 2025 Letter to Shareholders
VANCOUVER, Washington, March 18, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As envisioned, 2025 is unfolding to be an exciting year...
Octane’s First ‘Neuro Tech Forum’: Cutting-Edge Innovations and Global Leaders Converge in Newport Beach, April 2025
Southern California's Leading Medtech Octane's Premier Event Unites Global Stakeholders and Spotlights Innovations in Neuroscience and Technology for a Day...
VAS101, a Novel Curcumin Transdermal Formulation, Reverses Some Clinical Hallmarks of Aging
SUMMIT, N.J., March 17, 2025 /PRNewswire/ -- In a new study published in the journal GeroScience, VAS101 (Vasceptor®), a novel...
Baird Medical’s AI Tumor Ablation Surgical Robot Wins “Most Valuable Investment Award,” Pioneering AI and Robotics Integration in Healthcare
NEW YORK, March 17, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company") has been...
Hemostemix’s Pitch to Wall Street: ACP-01 Vascular Dementia Trial will Generate $5,365,000, Capture Data, as a Phase 1 Clinical Trial
Calgary, Alberta--(Newsfile Corp. - March 17, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or "HEM"), an...
Hyperfine and NVIDIA Collaborate to Revolutionize Neuroimaging with AI-Powered Innovation
Collaboration aims to make portable MRI faster, smarter, and more accessible worldwide. GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking...
Hyperfine and NVIDIA Collaborate to Revolutionize Neuroimaging with AI-Powered Innovation
Collaboration aims to make portable MRI faster, smarter, and more accessible worldwide. GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking...
New RAD202 Data Confirms Positive Tumor Uptake and Favorable Biodistribution
Data presented at European Molecular Imaging Meeting (EMIM 2025) for imaging with 68Ga-RAD202 confirms specific accumulation in the tumor, favorable...
CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates
-Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy...
Progress Update on Halberd, Athena GTX and Athena Telemedicine Partnership, LLC Joint Projects
The US Government Granted Athena GTX a $2,866,000 Final Development Contract Award!JACKSON CENTER, Pa., March 17, 2025 (GLOBE NEWSWIRE) --...
ProDentim Under Review: Why Taking Probiotics for Stronger Teeth & Healthier Gums is Trending
How Probiotics Are Transforming Dental Health and Redefining Oral HygieneTALLMADGE, Ohio, March 15, 2025 (GLOBE NEWSWIRE) -- In 2025, the...
NKGen Biotech To Present on Potential of Troculeucel for the Treatment of Neurodegenerative Diseases at the 13th Annual Alzheimer’s & Parkinson’s Drug Development Summit
SANTA ANA, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage...